{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=19", "query": { "intervention": "Chemotherapeutic Agent", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:27:57.184Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03907969", "title": "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "AZD7648", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 30, "start_date": "2019-10-09", "completion_date": "2022-12-07", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907969" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT04630756", "title": "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Haematological Malignancies" ], "interventions": [ { "name": "AZD4573", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 40, "start_date": "2021-02-17", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 4, "location_summary": "Duarte, California • La Jolla, California • Houston, Texas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630756" }, { "nct_id": "NCT00830973", "title": "The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Neoplasms", "Tamoxifen" ], "interventions": [ { "name": "Poor Metabolism Status Follow Up Therapy Considerations", "type": "OTHER" }, { "name": "CYP2D6 Inhibiting Drugs", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medco Health Solutions, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 184, "start_date": "2007-10", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2009-10-14", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 1, "location_summary": "Franklin Lakes, New Jersey", "locations": [ { "city": "Franklin Lakes", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00830973" }, { "nct_id": "NCT02855359", "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse, Large B-Cell, Lymphoma", "Follicular Lymphoma, Grade 3b", "Transformed Lymphoma / DLBCL" ], "interventions": [ { "name": "denintuzumab mafodotin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-08", "completion_date": "2018-05-15", "has_results": true, "last_update_posted_date": "2019-03-11", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855359" }, { "nct_id": "NCT00642746", "title": "Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2008-03", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-09-26", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642746" }, { "nct_id": "NCT00860041", "title": "Acute Pain Caused by Paclitaxel in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chemotherapeutic Agent Toxicity", "Neurotoxicity", "Pain", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pain questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2009-02", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 279, "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00860041" }, { "nct_id": "NCT03162224", "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Human Papilloma Virus" ], "interventions": [ { "name": "MEDI0457", "type": "DRUG" }, { "name": "CELLECTRA®5P device", "type": "DEVICE" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 35, "start_date": "2017-06-26", "completion_date": "2021-03-19", "has_results": true, "last_update_posted_date": "2022-08-25", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 14, "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162224" }, { "nct_id": "NCT07215910", "title": "Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Astrocytoma, IDH-Mutant, Grade 3" ], "interventions": [ { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Volume Modulated Arc Therapy", "type": "RADIATION" }, { "name": "Pencil Beam Scanning", "type": "RADIATION" }, { "name": "Intensity-Modulated Proton Therapy", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 408, "start_date": "2026-06-24", "completion_date": "2040-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 152, "location_summary": "Bakersfield, California • Duarte, California • Dublin, California + 119 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215910" }, { "nct_id": "NCT07100080", "title": "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Iza-bren", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-11-05", "completion_date": "2030-11-15", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-15T05:27:57.184Z", "location_count": 28, "location_summary": "Irvine, California • Orange, California • Edwards, Colorado + 22 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Edwards", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07100080" } ] }